Eliminating Preventable Blindness
Intelligent Retinal Imaging Systems (IRIS) provides diabetic retinopathy exam (DRE) screening services in the primary care setting. Founded by nationally recognized retina surgeon Dr. Sunil Gupta, IRIS offers an FDA 510(k)-approved medical device platform consisting of a cloud-based camera-agnostic tool and service to interpret DRE results. The company’s sophisticated technology detects blindness with 95% accuracy, with early detection reducing the risk of sight loss by 90%. Additionally, the platform offers a comprehensive end-to-end system/workflow integration and diagnosis (via remote reads), all while enabling ophthalmology referrals and billing for complex patients. Over 500 organizations rely on the IRS for retinal exams, contributing to 1.6 million images reviewed over time.
Date of investment: 2017
Sector: MedTech
Company status: Active
Associated team: Jeff Stolte (Board Director), Christina Warner
